Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease
F Kanwal, JH Shubrook, LA Adams, K Pfotenhauer… - Gastroenterology, 2021 - Elsevier
Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.
gastro. org. Scan this QR code to be taken directly to the website. Nonalcoholic fatty liver …
gastro. org. Scan this QR code to be taken directly to the website. Nonalcoholic fatty liver …
Current therapies and new developments in NASH
Non-alcoholic steatohepatitis is becoming the most important aetiology for advanced liver
disease. There has been important progress in the field in recent years and the complexity of …
disease. There has been important progress in the field in recent years and the complexity of …
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
ME Rinella, BA Neuschwander-Tetri, MS Siddiqui… - Hepatology, 2023 - journals.lww.com
Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
FE Mózes, JA Lee, EA Selvaraj, ANA Jayaswal… - Gut, 2022 - gut.bmj.com
Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic
fatty liver disease. The aims of this study were to evaluate the individual diagnostic …
fatty liver disease. The aims of this study were to evaluate the individual diagnostic …
[HTML][HTML] Non-alcoholic fatty liver disease: A patient guideline
SM Francque, G Marchesini, A Kautz, M Walmsley… - JHEP reports, 2021 - Elsevier
This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …
Impact of non-invasive biomarkers on hepatology practice: past, present and future
Over the last two decades, there have been tremendous advances in the non-invasive
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches …
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches …
Nonalcoholic fatty liver disease 2020: the state of the disease
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide
prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic …
prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic …
Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: a systematic review
Abstract Background & Aims Fibrosis is the strongest predictor for long‐term clinical
outcomes among patients with non‐alcoholic fatty liver disease (NAFLD). There is growing …
outcomes among patients with non‐alcoholic fatty liver disease (NAFLD). There is growing …
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based …
Background Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver
disease worldwide. Many individuals have risk factors associated with NAFLD, but the …
disease worldwide. Many individuals have risk factors associated with NAFLD, but the …
[PDF][PDF] Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH)
are highly prevalent in the United States, where they are a growing cause of cirrhosis and …
are highly prevalent in the United States, where they are a growing cause of cirrhosis and …